A Louisiana appeals court has overturned a Risperdal settlement to Johnson & Johnson’s advantage. Bloomberg reports that the court tossed a $257.7 million deceptive marketing verdict, saying prosecutors failed to provide enough evidence of wrongdoing.
Despite the local win for J&J, Louisiana is just a minor point in a bigger marketing tangle, which includes allegations from the Department of Justice that the drugmaker’s marketing strategies triggered fraudulent government payments for the anti-psychotic, and allegations of tying speaker fees to prescription rates, among others.
